Labcorp trades 4% below analyst fair value after HPV deal
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Labcorp Holdings partnered with Waters Corporation to launch the FDA-approved BD Onclarity HPV Assay nationwide, expanding its cervical cancer screening capabilities. Shares trade at $328.95 against a $344.25 fair value estimate, roughly 4% undervalued, with an analyst target of $345.12. Ratings stand at 13 Buy, 4 Hold and 1 Sell.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.